Lantus® (insulin glargine)
Phase 1Completed 0 watching 0 views this week💤 Quiet
32
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Hyperglycemia
Conditions
Hyperglycemia, Diabetes Mellitus
Trial Timeline
Feb 1, 2002 → —
NCT ID
NCT00348972About Lantus® (insulin glargine)
Lantus® (insulin glargine) is a phase 1 stage product being developed by Sanofi for Hyperglycemia. The current trial status is completed. This product is registered under clinical trial identifier NCT00348972. Target conditions include Hyperglycemia, Diabetes Mellitus.
Hype Score Breakdown
Clinical
10
Activity
5
Company
9
Novelty
3
Community
2
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00348972 | Phase 1 | Completed |
Competing Products
9 competing products in Hyperglycemia
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Exenatide + Insulin | Eli Lilly | Phase 2/3 | 65 |
| Human regular insulin + Insulin lispro + Insulin glargine | Eli Lilly | Phase 3 | 77 |
| Dapagliflozin + Sliding scale insulin | AstraZeneca | Approved | 85 |
| GLP-1 control + GLP-1 and Exendin(9-39) 300 + saline control + GLP-1 and Exendin(9-39) 600 + GLP-1 and Exendin(9-39) 900 + GLP-1 and Exendin(9-39) 1200 | Merck | Phase 1 | 33 |
| liraglutide + placebo | Novo Nordisk | Pre-clinical | 22 |
| Olanzapine + Ziprasidone | Pfizer | Pre-clinical | 22 |
| NPH insulin plus Complete Insulin Orders + Complete Insulin Orders | Sanofi | Approved | 84 |
| insulin glargine + insulin glargine + insulin glargine | Sanofi | Approved | 84 |
| insulin glargine recombinant + therapeutic insulin | Sanofi | Phase 3 | 76 |